Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS - biomarcha-data-human-serum-08-06-2020

ABSTRACT: Serum samples from Chagas disease patients, pre-treatment and 2, 6, 12 and 24 months post-treatment with benznidazole and extracted with methanol. Polar C18 chromatography. PRM analysis of acylcarnitine metabolites.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Human

SUBMITTER: Laura-Isobel McCall

PROVIDER: MSV000086025 | GNPS | Wed Aug 26 21:41:00 BST 2020

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

biomarcha-data-human-serum-08-06-2020

Project description:Serum samples from Chagas disease patients, pre-treatment and 2, 6, 12 and 24 months post-treatment with benznidazole and extracted with methanol. Polar C18 chromatography. PRM analysis of acylcarnitine metabolites.

2020-08-26 | MSV000086025 | MassIVE

Notch receptor expression in Trypanosoma cruzi infected Human Umbilical Vein Endothelial Cells treated with benznidazole or aspirin as revealed by microarray analysis

Project description:Chagas disease is a parasitic infection originally endemic to latinamerican countries but now spreaded worldwide that can be transmitted congenitally. Current specific therapy involves benznidazole, however, other therapies may modify gene expression that can change genetic expression profile, allowing cell programming to provide a more unfavorable environment for intracellular parasite development. Herein, microarray analysis was performed to Human Umbilical Vein Endothelial Cells (HUVEC), treated with benznidazole and the anti-inflammatory drugs aspirin or simvastatin, and infected with T. cruzi, the causative agent of Chagas disease.

2019-03-14 | GSE128270 | GEO

Chagas_human_serum_PRM_biomarkers_of cure

Project description:Patients treated with benznidazole. Serum samples collected over time following treatment. Candidate biomarkers of cure assessed by PRM. Polar C18 column, positive mode MS.

2022-02-04 | MSV000088785 | MassIVE

Total RNA sequencing of Plasmodium falciparum field parasites 2018-2020 collected from Cambodia and Vietnam

Project description:The objective of this study is to characterize the gene expression signatures associated with in vivo artemisinin resistance phenotype and its transcriptional response to Artemisinin Combination Therapy (ACT) or Triple artemisinin combination therapy (TACT). Using stranded RNA-seq protocol expression profiles of Plasmodb annotated transcripts along with anti-sense, alternatively spliced and non-coding isoforms expressed in clinical isolates were generated for 310 pre-treated, 300 post-treated and 24 timepoints from the intra-erythrocyte development cycle.

2024-09-30 | GSE242548 | GEO

46986158-75a7-4bd5-9c84-274e0ec775c0 - samples

Project description:NABUCCO cohort 1 sequencing data. The dataset includes: * Whole exome DNAseq pre-treatment on tumor samples (n=24) matched with blood samples (n=24) * RNAseq pre-treatment on tumor samples (n=18) * RNAseq post-treatment on tumor samples (n=18). Not all pre-treatment samples are linked with pre-treatment samples * High coverage Whole exome DNAseq on pre-treatment tumor samples (n=3) matched with post-treatment metastasized lymph nodes isolated with laser microdissection (n=3) * All samples are labelled with the response phenotype (Complete Responder or Non-Complete Responder)

| EGAD00001006250 | EGA

Project description:24 months seq

| PRJNA1140303 | ENA

Gene expression profile of subcutaneous panniculitis-like T-cell Lymphoma

Project description:Gene expression profiling from skin tissue samples. Pre-treatment = sample taken before any treatment at the time of SPTL diagnosis, post-treatment 1 = sample taken during treatment after 3 to 6 months of diagnosis and post-treatment 2 = sample taken during treatment after 6 to 12 months of diagnosis.

2014-07-01 | E-MTAB-910 | biostudies-arrayexpress

GNPS - urine biomarkers of Chagas disease treatment success (mice)

Project description:Mice were infected with Trypanosoma cruzi parasites, followed by treatment with benznidazole. Controls include uninfected mice and mice treated with isoproterenol to induce cardiac failure through chemical mechanisms. Urine was collected pre- and post-treatment and extracted using methanol, followed by LC separation using polar C18 LC and positive mode MS/MS data acquisition.

2021-11-23 | MSV000088436 | GNPS

Scleroderma and Gleevec treatment

Project description:Total RNA was extracted from skin biopsies before and after imatinib (Gleevec) treatment using Qiagen RNeasy fibrous tissue kit. RNA was amplified using the Ambion Amino Allyl MessageAmp II aRNA kit. Amplified skin RNA (labeled with Cy5) and amplified Stratagene Human Universal Reference RNA (labeled with Cy3) were competitively hybridized to HEEBO microarrays in duplicate as described (http://www.microarray.org/sfgf/heebo.do). 161a/b: Patient 1, pre-Gleevec treatment 170a/b: Patient 1, post-Gleevec treatment 215a/b: Patient 2, pre-Gleevec treatment 232a/b: Patient 2, post-Gleevec treatment A compound treatment design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed. Compound Based Treatment: Treated with 100 mg Gleevec twice daily for 3 months or 200 mg Gleevec daily for 6 months Keywords: compound_treatment_design

2009-03-31 | GSE11130 | GEO

Explorative study of stimulated saliva proteome in head and neck cancer patients pre-and post-treatment

Project description:Abstract Objectives: to compare saliva proteome of head and neck cancer patients prior to treatment and six months post-treatment with that of controls and relate the level of mucins with patient’s problems with dry mouth, sticky saliva and swallowing. Design: Five dentate patients and five age and gender matched controls were included. The stimulated salivary secretion rate was determined and saliva stored at -80°C. After thawing, 30 mg of each sample and a reference was trypsin digested. The digested peptides were analyzed by mass spectrometry. The relative abundances were transformed to log2 and significant differences determined. Relative abundances of mucins were compared with patient’s problems with dry mouth, sticky saliva and swallowing. Results: 966 proteins with ≥ 2 unique peptides were found. Compared with controls, 21 proteins were found in lower relative abundances and 30 in higher at pre-treatment and 28 proteins in lower relative abundances and 24 proteins in higher post-treatment. Regarding saliva proteins, a lower relative abundance of Cystatins was detected pre-treatment and lower relative abundances of Cystatin, Cysteine-rich secretory protein 3, Lactoperoxidase, Prolactin-inducible protein and Proline-rich protein 4 post-treatment. No clear relation between mucins and dry mouth, sticky saliva and problems with swallowing was detected. Conclusion: Decreases in several saliva proteins post cancer treatment might lead to a reduced defense against oral disorders. Knowledge about changes in saliva proteins in connection with oral cancer treatment is important for planning dental care for these patients.

2024-10-14 | PXD047500 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data